A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

Type of Cancer
Genito-Urinary

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.